Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Type 2 Diabetes, Obesity, Semaglutide, GLP-1. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
GLP-1 Receptor Agonist-Induced Muscle Mass Evaluation and Retention
Overview
The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss. This study involves (3) in-person study visits. At each visit, participants will be asked to: * Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs. * Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength. * Complete questionnaires related to demographics, health information, physical activity, and nutrition. * Have a blood sample collected from a vein in your arm. * Have your blood levels assessed through three finger pricks. * Complete three days of food records.
Primary outcome measures
- Changes in skeletal and cardiac muscle mass [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- Adults 18-80 years of age
- Starting semaglutide for type 2 diabetes or weight loss
- Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)
Exclusion criteria
- Current use of semaglutide for more than 2 weeks
- Major recent heart issues or other severe health conditions
- Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)
- Dependence on a mobility aid (unable to participate in exercise MRI)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
Canada · 1 center
- Mazankowski Alberta Heart Institute — Edmonton
Identifiers
NCT: NCT07272837 · Pro00153724